COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Zinc study #2 of 10
5/8 Late treatment study
Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed)
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
Source   PDF   Share   Tweet
Retrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation.
Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56, p = 0.002; increase in being discharged home, adjusted OR 1.53, p = 0.008.

Carlucci et al., 5/8/2020, retrospective, peer-reviewed, 6 authors.
risk of combined death/hospice, 37.8% lower, RR 0.62, p = 0.002, treatment 411, control 521, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 10 studies
Please send us corrections, updates, or comments.
Submit